Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Kampmann Melissa S.

Kampmann Melissa S. reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 50.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,515 shares of the medical equipment provider's stock after selling 18,525 shares during the quarter. Kampmann Melissa S.'s holdings in Hologic were worth $1,335,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Royal London Asset Management Ltd. increased its holdings in Hologic by 2.8% during the 4th quarter. Royal London Asset Management Ltd. now owns 344,465 shares of the medical equipment provider's stock worth $24,832,000 after purchasing an additional 9,454 shares during the period. Xponance Inc. increased its stake in shares of Hologic by 3.3% during the fourth quarter. Xponance Inc. now owns 34,027 shares of the medical equipment provider's stock valued at $2,453,000 after buying an additional 1,083 shares during the period. Boston Partners increased its stake in shares of Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after buying an additional 1,602,463 shares during the period. Intech Investment Management LLC lifted its stake in Hologic by 64.2% in the fourth quarter. Intech Investment Management LLC now owns 92,300 shares of the medical equipment provider's stock worth $6,654,000 after acquiring an additional 36,104 shares during the period. Finally, Generali Asset Management SPA SGR bought a new position in Hologic during the 4th quarter worth about $4,040,000. Institutional investors own 94.73% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

HOLX has been the subject of several recent research reports. Royal Bank of Canada reduced their price target on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a report on Thursday, February 6th. Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. William Blair reiterated an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Stephens restated an "overweight" rating and set a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. Finally, BNP Paribas upgraded Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $84.62.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded up $0.42 on Monday, hitting $61.89. 2,689,974 shares of the company were exchanged, compared to its average volume of 1,754,748. The firm has a market capitalization of $13.89 billion, a P/E ratio of 19.52, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 1-year low of $60.34 and a 1-year high of $84.67. The stock's 50 day moving average price is $66.06 and its 200 day moving average price is $73.94.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.